RecruitingNot Applicable

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

United States80 participantsStarted 2023-02-07

Plain-language summary

This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years.
✓. Diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treating physician or tumor board.
✓. Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician.
✓. Ability to understand a written informed consent document and the willingness to sign it.

Exclusion criteria

✕. Age \<18 years.
✕. Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma
✕. Tumor does not have a KRAS G12R mutation.

What they're measuring

The number of subjects with no progression.

Timeframe: 6 months

Trial details

NCT IDNCT05630989

SponsorMandana Kamgar, MD

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-08-01

Contact for this trial

Mandana Kamgar, MD, MPH

414-805-4600 mkamgar@mcw.edu

View on ClinicalTrials.gov More Pancreatic Ductal Adenocarcinoma trials